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Background/aim: Acute kidney injury (AKI) is a serious morbidity in premature neonates. The aim of this study was to determine the
incidence of AKI and to evaluate its impact on morbidity and mortality in very premature infants.
Materials and methods: This retrospective cohort study was conducted in the neonatal intensive care unit (NICU). A total of 410
preterm infants who were born before 32 gestational weeks were screened and 318 were included in this analysis. AKI was defined
according to the modified neonatal Kidney Disease: Improving Global Outcomes criteria.
Results: The incidence of AKI was 32.1% (102/318). Regression analyses revealed that lower gestational age, vasopressor use, and
hemodynamically significant patent ductus arteriosus were significantly associated with an increased risk for AKI. After adjustment for
potential confounders, those with AKI had a higher risk of death before 36 weeks of corrected gestational age (adjusted hazard ratio:
3.02, 95% confidence interval 1.47– 6.22). Additionally, the AKI group had a higher rate of bronchopulmonary dysplasia (BPD) (46%
vs. 24%, p < 0.001) and longer hospital stay with a mean difference of 38 days.
Conclusion: AKI is common in very premature neonates and associated with higher mortality, longer hospital stay, and BPD.
Identification of risk factors and preventive strategies for AKI may improve the outcomes in this vulnerable population.
Key words: Acute kidney injury, very preterm infants, mortality, neonatal KDIGO

1. Introduction
Nephrogenesis is completed at about 36 weeks of
gestation. Premature neonates are prone to develop acute
kidney injury (AKI) due to kidney immaturity and high
risk of exposure to hemodynamic changes, infections
and nephrotoxic medications [1,2]. Surviving premature
infants are also at risk for chronic kidney disease later
in life [2]. Studies on pediatric and adult patients have
shown that even a small change in serum creatinine (SCr)
was associated with increased mortality [3,4]. Similar
associations were noted for premature infants in recent
studies [5–10].
The incidence of AKI in preterm neonates has been
reported to range from 12 to 48%. This large variation
could be the result of quite different definitions of AKI
[2]. Newer AKI definitions such as modified pediatric risk,
injury, failure, loss and end-stage renal disease (pRIFLE)
[11], acute kidney injury network (AKIN) [12] and Kidney
Disease: Improving Global Outcomes (KDIGO) [13] have
made progress in diagnosing AKI in the pediatric and adult
population. These definitions are based on percentage of

increase in serum creatinine (SCr) and oliguria. To adopt
a standardized AKI definition for neonates, a modified
KDIGO definition was proposed by Jetton and Askenazi
(Table 1) [14]. However, there are limited studies using
this new definition of AKI in premature infants.
The aim of this study was to investigate the incidence
and risk factors of AKI in very premature newborns
using the neonatal KDIGO definition, and to evaluate the
relationship between AKI and adverse neonatal outcomes.
2. Materials and methods
2.1. Study population
This retrospective cohort study was performed in a level
3 neonatal intensive care unit (NICU) from January 2017
to December 2019. A total of 410 infants who were born
before 32 gestational weeks were screened. Thirty-six
infants who died within the first 48 h of life, 19 infants
with major congenital anomalies, and 37 infants with
insufficient SCr data were excluded from the study.
Consequently, 318 infants were available for this analysis
(Figure 1). This study was approved by the Hospital Ethics
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Table 1. Modified neonatal acute kidney injury Kidney Disease: Improving Global. Outcomes criteria

a

Stage

Serum creatinine (SCr)

Urine output

0

No change in SCr or increase < 0.3 mg/dL

≥ 0.5 mL/kg/h

1

SCr increase ≥ 0.3 mg/dL within 48 h or
SCr increase ≥ 1.5 to 1.9 referencea SCr within 7 d

< 0.5 mL/kg/h for 6-12 h

2

SCr increase ≥ 2 to 2.9 referencea SCr

< 0.5 mL/kg/h for ≥ 12 h

3

SCr increase ≥ 3 reference SCr or SCr ≥ 2.5 mg/dL or receipt of dialysis

< 0.3 mL/kg/h for ≥ 24 h or anuria for ≥ 12 h

a

: Reference SCr was defined the lowest previous SCr.

410 very preterm infants
GA < 32 weeks

36 infants died in
the first 48h of life

374 infants survived beyond
48 h of life

37 infants had only
one SCr data

337 infants had
two or more SCr data

19 infants had
congenital anomalies

318 infants were
enrolled

Figure 1. Flowchart of the selection of patients. GA, gestational age; SCr, serum
creatinine.

Committee, on 1 June 2020, with a registration number of
2020/0413.
2.2. Renal function tests
For all study patients, SCr values measured as a part
of routine care were recorded. In our NICU, a routine
biochemistry panel including SCr was obtained at least
every 2 days during the first week of life in these infants;
then once a week. In case of clinical deterioration, SCr
levels were monitored for at least the next 48 h. AKI was
diagnosed according to the modified neonatal KDIGO
criteria which takes into account the increase in SCr
compared to a reference value rather than a single cutoff
value (Table 1) [14]. Based on these criteria, AKI was
defined as a SCr rise of ≥ 0.3 mg/dL within 48 h or ≥1.5
times the reference value within 7 days. Creatinine values
obtained during the first two days of life may reflect
maternal creatinine levels [15] and the postnatal transition
period [16]. Therefore, reference SCr was defined as the
lowest previous SCr value after the first 48 h of age. Urine
output criteria were not included because it was difficult to
measure in preterm infants. In cases with more than one
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AKI episode, the highest AKI stage was included in the
analysis.
2.3. Data collection
Hospital electronic medical records and patient files were
reviewed for data collection. Maternal characteristics
included diagnosis of preeclampsia, diabetes, prolonged
rupture of membranes (PROM) for more than 18 h,
chorioamnionitis, and the administration of antenatal
steroids. Chorioamnionitis was defined as the presence
of fever and treatment with intravenous antibiotics.
Demographic factors included gestational age (GA),
birth weight, sex, delivery mode, Apgar score at 5 min,
and small for gestational age status. The following
clinical characteristics were also documented: need
for vasopressors and high frequency ventilation,
hemodynamically significant patent ductus arteriosus
(HSPDA), any grade intraventricular hemorrhage (IVH),
culture positive sepsis, and use of nephrotoxic medication
(vancomycin and gentamicin).
In our unit, echocardiography was performed by
a pediatric cardiologist in very premature newborns
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between the 3rd to 5th days of life. As per our unit policy,
ibuprofen was used as the first choice for patients with
HSPDA, and paracetamol treatment was given if there is
a contraindication to the use of cyclooxygenase inhibitors.
Surgical ligation was performed in patients with HSPDA
despite three cycles of medical therapy. All patients were
evaluated in the 3 days of life for IVH and then weekly by
a neonatologist.
The primary outcome was survival to discharge
or 36 weeks of corrected gestational age (CGA).
Bronchopulmonary dysplasia (BPD) and length of
hospital stay were evaluated as secondary outcomes. BPD
was defined as oxygen dependency at 36 weeks of CGA.
2.4. Statistical analysis
SPSS 23.0 for Windows program was used for data
analysis. The distribution of the sample was checked by
the Shapiro–Wilk test. Normally distributed data were
represented by the mean and standard deviation (SD),
whereas skewed data was represented by the median and
interquartile range (IQR). Continuous data were compared
using the Student’s t-test or Mann–Whitney U test. Chisquared tests were used for the evaluation of categorical
data. Variables with p < 0.2 on univariate analysis were
included in a multivariate logistic regression model. A
stepwise backward selection approach was used to identify
independent risk factors for AKI. Cox regression analysis
was performed for mortality before 36 weeks of CGA.
Variables with p < 0.2 in the univariate test were included
in the multivariate model and the stepwise backward
selection was performed to determine independent
predictors of mortality. Collinearity among the covariates
was tested.

3. Results
The study included 164 males (51.6%) and 154 females
(48.4%). The mean gestational age and birth weight were
28.1 ± 2.3 weeks (23–31 weeks) and 1129.6 ± 320.6 g (410–
1910 g), respectively. AKI was diagnosed in 102 of 318
patients, the incidence of AKI was 32.1%. When classified
according to the modified KDIGO criteria, 68 infants
(67%) were stage 1, 19 infants (19%) were stage 2 and 15
infants (15%) were stage 3. The majority of infants with
AKI had GA < 28 weeks and birth weight < 1000 g (Tables
2 and 3). AKI episodes mostly occurred during the first
week of life (73 of 102) (median: 5 days, IQR: 5–7 days).
Patient characteristics of the infants with and without
AKI are compared in Table 4. Maternal factors including
diabetes, preeclampsia, PROM, chorioamnionitis and
antenatal steroid use were not significantly different
between infants with and without AKI. Infants with AKI
had lower GA, birth weight and 5 min Apgar scores. In
univariate analysis, vasopressor use, HSPDA, IVH, need
for high frequency ventilation, culture proven sepsis, and
exposure to nephrotoxic antibiotics were all significantly
associated with AKI. After controlling for all confounders
with univariate p < 0.2; lower GA, vasopressor use, and
HSPDA were identified as risk factors for AKI (Table 5).
Out of the 318 very premature infants, 41 (12.9) died
before 36 weeks of CGA. Infants with AKI had a higher
rate of mortality (29% vs. 5%). In univariate analysis, AKI
was strongly associated with mortality with a crude hazard
ratio (HR) of 5.73 (95% CI 2.78–11.78; p < 0.001). Other
variables significantly associated with mortality included
GA, birth weight, vasopressor use, high frequency
ventilation, HSPDA, IVH, and culture proven sepsis

Table 2. Incidence of AKI stratified by gestational age.
AKI

< 750 g
(n = 63)

750–1000 g
(n = 70)

11000–1250
(n = 97)

> 1250 g
(n = 88)

Total
(n = 318)

p value

No

23 (36.5%)

35 (50%)

78 (80.4%)

80 (90.1%)

216 (67.9%)

< 0.001

Stage 1

25 (39.7%)

21 (30%)

16 (16.5%)

6 (6.8%)

68 (21.4%)

Stage 2

8 (12.7%)

8 (11.4%)

3 (3.1%)

0 (0%)

19 (6%)

Stage 3

7 (11.1%)

6 (8.5%)

0 (0%)

2 (2.3%)

15 (4.7%)

Table 3. Incidence of AKI stratified by birth weight.
AKI

< 26 weeks
(n = 76)

26–27 weeks
(n = 76)

28–29 weeks
(n = 87)

30–31 weeks
(n = 79)

Total
(n = 318)

p value

No

39 (51.3%)

42 (55.3%)

69 (79.3%)

66 (83.5%)

216 (67.9%)

< 0.001

Stage 1

23 (30.3%)

22 (28.9%)

12 (13.8%)

11 (13.9%)

68 (21.4%)

Stage 2

8 (10.5%)

6 (7.9%)

4 (4.6%)

1 (1.3%)

19 (6%)

Stage 3

6 (7.9%)

6 (7.9%)

2 (2.3%)

1 (1.3%)

15 (4.7%)
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Table 4. Demographic and clinical characteristics of patients with and without AKI.
No AKI
(n = 216)

AKI
(n = 102)

p value

Maternal diabetes

20 (9.3%)

11 (10.8%)

0.669

Preclampsia

63 (29.2%)

22 (21.6%)

0.153

PROM

40 (18.5%)

24 (23.5%)

0.298

Chorioamnionitis

18 (8.3%)

12 (11.8%)

0.329

Antenatal steroid

161 (74.5%)

70 (68.6%)

0.270

Gestational age (week)*

29.1 ± 2.1

27.5 ± 2.2

< 0.001

Birth weight, (g)*

1320.0 ± 253.4

894.5 ± 251.9

< 0.001

Cesarean delivery

158 (73.1%)

66 (64.7%)

0.124

Male sex

115 (53.2%)

49 (48%)

0.386

SGA

25 (11.6%)

16 (15.7%)

0.307

Apgar at 5 min**

8 (6, 9)

7 (5, 8)

< 0.001

Vasopressor use

22 (10.2%)

37 (36.3%)

0.001

Culture proven sepsis

32 (14.8%)

25 (24.5%)

0.035

HSPDA

34 (15.7%)

41 (40.2%)

< 0.001

HFV

45 (20.8%)

34 (32.4%)

0.016

IVH

27 (12.5%)

23 (22.5%)

0.022

Nephrotoxic medication

171 (79.2%)

92 (90.2%)

0.015

* : mean ± standard deviation.
** : median (interquartile range).
AKI, acute kidney injury; PROM, prolonged rupture of membrane; SGA, small for
gestational age; HSPDA, hemodynamically significant patent ductus arteriosus; HFV,
high frequency ventilation; IVH, intraventricular hemorrhage.
Table 5. Results of logistic regression of risk factors for AKI.
Variable

Odds ratio ( 95% CI)*

p value

Gestational age

0.68 (0.59–0.78)

< 0.001

HSPDA

1.92 (1.04–3.55)

0.037

Vasopressor use

2.68 (1.37–5.25)

0.004

*: Adjusted for gestational age, cesarean delivery, Apgar scores
at 5 min, need for high frequency ventilation, vasopressor use,
intraventricular hemorrhage, hemodynamically significant
patent ductus arteriosus, culture proven sepsis, nephrotoxic
medication use and maternal preeclampsia.
AKI, acute kidney injury; HSPDA, hemodynamically significant
patent ductus arteriosus.

(Table 6). After controlling for confounding variables with
univariate p < 0.2; AKI remained a predictor of mortality
(adjusted HR: 3.01, 95% CI: 1.47–6.22, p = 0.003) (Table
6, Figure 2A). When stratified by stage, all AKI stages
including stage 1 were associated with mortality (Table 6,
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Figure 2B). Among the 277 survivors, patients with AKI
had a higher rate of BPD (46% vs. 24%, p < 0.001) and
longer hospital stay (median: 84 days, IQR: 67.5–103.5
days vs. median: 45 days, IQR: 33–60 days, p < 0.001).
After adjustment for GA and birth weight, AKI was
associated with a higher rate of BPD (adjusted OR 1.91
95% CI 1.05–3.47, p = 0.033).
4. Discussion
In this study, we demonstrated that one-third of very
premature infants developed AKI. Perinatal factors
including lower GA, vasopressor use, and presence of
HSPDA were identified as significant risk factors for AKI.
AKI was strongly associated with mortality before 36
weeks of CGA.
The incidence of AKI in very premature neonates
in our NICU was 32.1%. However, not including urine
output criteria in AKI diagnoses might result in an
underestimation of this incidence. Using the same KDIGO
SCr criteria, Stojanovic et al. [9] found that AKI developed
at a rate of 26% in all premature infants and 39% in very
low birth weight (VLBW, < 1500 g) premature infants. In
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Table 6. Predictors of mortality before 36 weeks of corrected gestational age.
Crude hazard ratio
(95% CI)

p value

Gestational age (week)

0.61 (0.52–0.72)

< 0.001

Birth weight (100 g)

0.73 (0.65–0.83)

< 0.001

Male sex

1.44 (0.78–2.67)

0.241

Apgar at 5 min,

0.82 (0.66–1.01)

0.065

Small for gestational age

1.71 (0.79–3.71)

0.174

Vasopressor use

8.35 (4.17–16.71)

< 0.001

Culture proven sepsis

4.78 (2.47–9.25)

< 0.001

Significant patent ductus arteriosus

2.83 (1.53–5.25)

0.001

High frequency ventilation

2.37 (1.27–4.41)

0.007

Intraventricular hemorrhage

3.00 (1.62–5.55)

< 0.001

Nephrotoxic medication

2.11 (0.51–8.78)

0.305

Any acute kidney injury

5.73 (2.78–11.78)

< 0.001

Acute kidney injury stage 1

4.36 (1.96–9.69)

< 0.001

Acute kidney injury stage 2

9.68 (3.91–23.96)

< 0.001

Acute kidney injury stage 3

7.29 (2.63–20.21)

< 0.001

Maternal diabetes

1.00 (0.44–2.29)

0.982

Preclampsia

0.53 (0.20–1.43)

0.213

Prolonged rupture of membrane

1.86 (0.96–3.60)

0.062

Chorioamnionitis

1.64 (0.69–3.89)

0.265

Cesarean delivery

0.79 (0.42–1.50)

0.483

Any acute kidney injury

3.02 (1.47–6.22)

0.003

Acute kidney injury stage 1

2.37 (1.08–5.20)

0.032

Acute kidney injury stage 2

4.27 (1.48–12.31)

0.007

Acute kidney injury stage 3

5.63 (2.07–15.30)

0.001

Univariate model

Multivariate model#

Cox proportional hazard ratios for GA per week increase, birth weight per 100 g
increase, Apgar scores per point increase, and categorical variables compared with
any AKI, stage 1 AKI, stage 2 AKI, stage 3 AKI, and absence of AKI.
# : Control for 5 min Apgar score, small for gestational age, vasopressor use. culture
proven sepsis, significant PDA, need for high frequency ventilation, IVH, and
PROM

the multicenter, multinational AWAKEN cohort study
[17], the incidence of AKI was 48% in newborns with GA
< 28 weeks and 18% in newborns with GA > 28 weeks. In
our study, AKI occurred in 71 (50%) of 142 infants with
GA < 28 weeks. However, in another study by Stojanovic
et al. [8], they showed that 44% (85/195) of premature
infants had AKI. Abdelaal et al. [18] performed a study on
60 premature infants with respiratory distress and found
that AKI developed at a rate of 40%. Although similar
diagnostic criteria were used in our study and the above
studies, there was a wide difference in the incidence of

AKI. This can be attributed to the differences in the patient
characteristics in terms of risk factors, overall sickness, and
management methods. Similar to previous studies [17], we
found that majority (67%) of AKI cases were stage 1.
We found that a lower GA, vasopressor use, and the
presence of HSPDA were independent risk factors for
AKI in very preterm neonates. The incidence of AKI was
inversely proportional to the gestational age. This might
be explained by the increasing risk of exposure to AKI risk
factors. Whereas, after controlling all possible risk factors,
a lower GA remained as an independent risk for AKI.
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Figure 2. Survival curve for patient with AKI.

PDA is serious morbidity associated with an increased
risk of IVH, BPD, and death in preterm infants [19]. An
HSPDA with shunting of blood across the ductus results
in compromised systemic perfusion and pulmonary
overflow. Systemic hypoperfusion could lead to renal
injury. Ibuprofen, a nonsteroidal antiinflammatory
(NSAID) medication, used to treat PDA could worsen the
problem [20]. On the other hand, NSAID exposure might
have beneficial renal effects as a result of ductal closure
[21]. Our data suggested that HSPDA was significantly
associated with AKI. However, we did not analyze the
effect of ibuprofen on the development of AKI separately.
Future studies on the relationships between AKI and
NSAID exposure in PDA treatment would be useful.
The need for vasopressor support reflects the higher
disease severity in newborns [22]. Our results supported
that the need for vasopressor support was significantly
associated with AKI. Although vasopressor use and
HSPDA were associated with AKI, their causative effect
needs to be explained. As a marker of kidney function, a rise
in SCr level occurs late after kidney injury. Also, HSPDA
or severe hypotension requiring vasopressors usually
develops during the first week of life as AKI episodes.
Thus, kidney injury might promote these comorbidities.
Previous studies have shown relationship between
neonatal AKI and vancomycin use or sepsis [8,23].
Nephrotoxicity has been reported in 2 to 20% of newborns
treated with vancomycin [8]. However, a cohort study
using propensity score matching reported no significant
association between vancomycin and AKI [24]. In our
study, culture positive sepsis and nephrotoxic antibiotics
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use were more frequent in infants with AKI, but after
adjustment other covariates, no significant association
was observed between AKI and sepsis or nephrotoxic
antibiotic use. However, we did not have data on the
duration of nephrotoxic antibiotic exposure which might
affect our results. These variations can also be explained
by the differences in patient characteristics in studied
populations.
Prenatal factors such as maternal diabetes and
preeclampsia have been identified as protective factors
for neonatal AKI [17,22]. In our study, although not
significant, the incidence of AKI was lower in infants of
mothers with preeclampsia. Other prenatal factors did
not differ between infants with and without AKI. Further
case-control studies with a larger sample size are required
to explain the contribution of these factors in AKI
development.
The impact of AKI in premature infants on survival and
other outcomes has become the focus of interest in recent
studies. In a case-control study, Askenazi et al. [5] showed
a two-fold increase in the probability of death for a small
increase (1 mg/dL) in SCr. In a study of 1461 premature
infants (GA of < 33 weeks) conducted by Bruel et al. [25],
AKI was associated with higher mortality. In our study,
AKI reduced overall survival at 36 weeks of CGA in very
premature infants (adjusted HR 3.0). Particularly, 26%
of infants with stage 1 AKI died before 36 weeks of CGA
and stage 1 AKI was associated with increased mortality.
Lassnigg et al. [26] previously demonstrated that minimal
elevation of SCr levels after cardiac surgery was associated
with serious implications. These findings suggest that even
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slightly elevated SCr in seriously ill patients require careful
evaluation and long-term follow-up. As an important
indicator of morbidity, the duration of hospital stay was
longer in infants with AKI. Additionally, these patients
had higher rates of BPD. The association between AKI
and prolonged ventilation has been described in critically
ill pediatric patients [27]. Starr et al. [28] retrospectively
evaluated 546 very premature infants and reported a
relationship between AKI and the development of BPD.
Animal-based researches also have shown that the
kidney has an important role in the stability of systemic
inflammation and cytokine balance and that kidney injury
may result in an inflammatory reaction in the lung [29,30].
Recent studies reported that AKI can lead to chronic
kidney disease and an impaired immune system later in
life [31]. Thus, serial follow-up of kidney functions of
surviving premature neonates is necessary.
Our study has some limitations. First, since SCr level
was not measured daily, the incidence and severity of
AKI might be underestimated. Second, because of the
retrospective design of the study, confounders related
to AKI and outcomes may not be effectively eliminated.
Third, SCr is not a good marker of renal injury and
estimated glomerular filtration rate since SCr generally

does not change until a 25%–50% decrease in kidney
function [32–34]. The novel biomarkers that have been
proposed to estimate AKI [35] were not used in our study.
Further prospective studies with novel biomarkers of renal
injury in addition to urine output are needed to improve
the detection of renal injury.
In conclusion, the results of our study show that AKI
is a common condition in very premature neonates and
can reduce survival at 36 weeks of CGA. Lower gestational
age, the presence of HSPDA, and vasopressor use were
found as independent risk factors for AKI. Surviving
infants after AKI had a higher rate of BPD and longer
hospital stay. Therefore, identification of risk factors and
preventive strategies for AKI may ameliorate the outcomes
in this vulnerable population. The effect of AKI on longterm kidney function and overall survival remains to be
elucidated.
Informed consent
The Ethics Committee of Göztepe Training and Research
Hospital approved the study protocol on 1 June 2020, with
a registration number of 2020/0413 and waived the need
for informed consent or parental permission.
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